Emerging roles for atypical antipsychotics in chronic post-traumatic stress disorder

References

• Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the national comorbidity survey. Arch. Gen. Psych. 52, 1048–1060 (1995).
   PubMed Web of Science ®Google Scholar
• Kulka RA, Schlenger WE, Fairbank JA et al. Trauma and the Vietnam war generation. Report of findings from the national Vietnam veterans readjustment study. Brunner/Mazel, NY, USA (1990).
   Google Scholar
• Hoge CW, Castro CA, Messer SC, McGurk K, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N. Engl. J. Med. 351, 13–22 (2004).
   PubMed Web of Science ®Google Scholar
• Resnick HS, Kilpatrick DG, Dansky BS, Saunders BE, Best CL. Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J. Consult. Clin. Psychology 61, 984–991 (1993).
   PubMed Web of Science ®Google Scholar
• Mueser KT, Goodman LB, Trumbetta SL et al. Trauma and posttraumatic stress disorder in severe mental illness. J. Consult. Clin. Psychol. 66, 493–499 (1998).
   PubMed Web of Science ®Google Scholar
• Mueser KT, Salyers MP, Rosenberg SD et al. Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates. Schizophr. Bull. 30, 45–57 (2004).
   PubMed Web of Science ®Google Scholar
• Seedat S, Stein MB, Oosthuizen PP et al. Linking posttraumatic stress disorder and psychosis. A look at epidemiology, phenomenology, and treatment. J. Nerv. Ment. Dis. 191, 675–681 (2003).
   PubMed Web of Science ®Google Scholar
• Gearon JS, Kaltman SI, Brown C, Bellack AS. Traumatic life events and PTSD among women with substance use disorders and schizophrenia. Psych. Serv. 54, 523–528 (2003).
   PubMed Web of Science ®Google Scholar
• Najavits LM, Runkel R, Neuner C et al. Rates and symptoms of PTSD among cocaine-dependent patients. J. Stud. Alcohol. 64, 601–606 (2003).
   PubMed Web of Science ®Google Scholar
• Najavits LM, Weiss RD, Shaw SR. The link between substance abuse and posttraumatic stress disorder in women. A research review. Am. J. Addict. 6, 273–283 (1997).
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Davidson JRT, Lecrubier Y et al. Consensus statement update on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 65(Suppl. 1), 55–62 (2004).
   PubMed Web of Science ®Google Scholar
• True WR, Rice J, Eisen SA et al. A twin study of genetic and environmental contributions to liablility for posttraumatic stress symptoms. Arch. Gen. Psych. 50, 257–264 (1993).
   PubMed Web of Science ®Google Scholar
• Yehuda R, Goier JA, Halligan SL, Meaney M, Bierer LM. The ACTH response to dexamethasone in PTSD. Am. J. Psychiatry 161, 1397–1403 (2004).
   PubMed Web of Science ®Google Scholar
• Southwick SM, Krystal JH, Bremner JD et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psych. 54, 749–758 (1997).
   PubMed Web of Science ®Google Scholar
• Bremner JD, Southwick SM, Charney DS. The neurobiology of posttraumatic stress disorder: an integration of animal and human research. In: Post-traumatic Stress Disorder: A Comprehensive Text. Saigh PA, Bremner JD (Eds). Allyn and Bacon, MA, USA, 103–143 (1999).
   Google Scholar
• Hamner MB, Diamond BI. Elevated plasma dopamine in posttraumatic stress disorder: a preliminary report. Biol. Psychiatry 33, 304–306 (1993).
   PubMedGoogle Scholar
• Segman RH, Cooper-Kazaz R, Macciardi F et al. Assocation between the dopamine transporter gene and posttraumatic stress disorder. Molecular Psychiatry 7, 903–907 (2002).
   PubMed Web of Science ®Google Scholar
• Noble EP. The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics 1, 309–333 (2000).
   PubMedGoogle Scholar
• Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am. J. Psychiatry 158, 1184–1190 (2001).
   PubMed Web of Science ®Google Scholar
• Foa EB, Keane TM, Friedman MJ. Guidelines for treatment of PTSD. J. Trauma Stress 13, 539–588 (2000).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Practice Guidelines for the Treatment of Patients with Acute and Chronic Post-traumatic Stress Disorder. J. Am. Psychiatr. Assoc. S161 (2004).
   Google Scholar
• Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry 62, 860–868 (2001).
   PubMed Web of Science ®Google Scholar
• Davidson J, Lipschitz A, Musgung JJ. Venlafaxine and sertraline in posttraumatic stress disorder: a placebo-controlled study. Poster presented at the 23rd Annual Conference of the Anxiety Disorders Association of America, March 27–30, Toronto, Canada (2003).
   Google Scholar
• Weathers FW, Keane TM, Davidson JRT. Clinician-Administered PTSD Scale: a review of the first ten years of research. Depress. Anxiety 13, 152–156 (2001).
   Google Scholar
• Baker DG, Diamond BI, Gillette G et al. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl.) 122, 386–389 (1995).
   PubMed Web of Science ®Google Scholar
• Hertzsberg MA, Feldman ME, Beckman JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD: a placebo-controlled trial in combat veterans. Ann. Clin. Psychiatry 12(2), 101–105 (2000).
   PubMedGoogle Scholar
• van der Kolk BA, Dreyfuss D, Micheals M et al. Fluoxetine in posttraumatic stress disorder. J. Clin. Psychiatry 55, 517–522 (1994).
   PubMed Web of Science ®Google Scholar
• Zohar J, Amital D, Miodownik C et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J. Clin. Psychopharmacol. 22, 190–195 (2002).
   PubMed Web of Science ®Google Scholar
• Foa EB, Davidson JRT, Frances A. Treatment of post-traumatic stress disorder. (Expert Consensus Guideline Series). J. Clin. Psychiatry 60(Suppl. 16), 3–76 (1999).
   PubMedGoogle Scholar
• Hamner MB, Robert S, Frueh BC. Treatment resistant posttraumatic stress disorder: strategies for intervention. CNS Spectrums 9(10), 740–752 (2004).
   PubMedGoogle Scholar
• Charney DS. Psychological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am. J. Psychiatry 161, 195–216 (2004).
   PubMed Web of Science ®Google Scholar
• Schnurr PP, Friedman MJ, Bernardy NC. Research on posttraumatic stress disorder: epidemiology, pathophysiology, and assessment. JCLP/In Session 58, 877–889 (2002).
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: toward testable hypotheses. Int. Clin. Psychopharmacol. 18, 121–132 (2003).
   PubMed Web of Science ®Google Scholar
• Kosten TR, Kosten TA. New medication strategies for comorbid substance use and bipolar affective disorders. Biol. Psychiatry 56, 771–777 (2004).
   PubMedGoogle Scholar
• Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann. Gen. Psychiatry 3, 4–13 (2004).
   Google Scholar
• Carson WH, Kitagawa H. Drug development for anxiety disorders: new role for atypical antipsychotics. Psychopharmacol. Bull. 38, 38–45 (2004).
   PubMedGoogle Scholar
• Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Psychopharmacol. 20, 9–11 (2005).
   PubMed Web of Science ®Google Scholar
• Ishak WW, Rapaport MH, Gotto JG. The effectiveness of atypical medications in depressive disorders. Curr. Psychiatry Rep. 6, 422–424 (2004).
   PubMedGoogle Scholar
• Miyamoto S, Duncan GE, Goff DC, Lieberman JA. Therapeutics of schizophrenia. In: Neuropsychopharmacology. Davis KL, Charney D et al. (Eds). Lippincott, Williams & Wilkins, PA, USA, 775–807 (2002).
   Google Scholar
• Kane JM, Barrett EJ, Casey DE et al. Metabolic effects of treatment with atypical antipsychotics. J. Clin. Psychiatry 65, 1447–1455 (2004).
   PubMed Web of Science ®Google Scholar
• Meltzer HT. What’s atypical about atypical drugs? Curr. Opin. Pharmacol. 4(1), 53–57 (2004).
   PubMed Web of Science ®Google Scholar
• Liegeosis JF, Ichikawa J, Meltzer HY. 5-HT2A receptor antagonism poteniates haloperidol dopamine release in rar medial prefronal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947(2), 157–165 (2002).
   PubMedGoogle Scholar
• Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin. Neurosci. 249(4), 90–98 (1999).
   PubMedGoogle Scholar
• Gupta S, Masand P. Aripiprazole: review of its pharmacology and uses in psychitaric disorders. Ann. Clin. Psychiatry 16(3), 155–166 (2004).
   PubMedGoogle Scholar
• Hamner MB. Psychotic features and combat-associated PTSD. Depress. Anxiety 5, 34–38 (1997).
   PubMedGoogle Scholar
• David D, Kutcher GS, Jackson EI et al. Psychotic symptoms in combat-related posttraumatic stress disorder. J. Clin. Psychiatry 60, 29–32 (1999).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Frueh C, Ulmer HG et al. Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol. Psychiatry 45, 846–852 (1999).
   PubMed Web of Science ®Google Scholar
• Sautter FJ, Uddo M, Brailey K et al. PTSD and comorbid psychotic disorder: comparison with veterans diagnosed with PTSD or psychotic disorder. J. Trauma Stress 12, 73–88 (1999).
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276 (1987).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Frueh BC, Ulmer HG et al. Psychotic features in chronic posttraumatic stress disorder and schizophrenia: comparative severity. J. Nerv. Ment. Dis. 188, 217–221 (2000).
   PubMed Web of Science ®Google Scholar
• Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl.) (2004) (In Press).
   PubMedGoogle Scholar
• Manguno-Mire GM, Johnson JE, Wiley J et al. Olanzapine versus haloperidol in the treatment of posttraumatic stress disorder with comorbid psychotic symptoms. Poster presented at the 55th Institute on Psychiatric Services, October 29th – November 2nd, Boston, MA, USA (2003).
   Google Scholar
• David D, DeFaria L, LaPeyra O et al. Adjunctive risperidone treatment in combat veterans with chronic PTSD. Poster presented at the 23rd Annual Conference of the Anxiety Disorders Association of America, March 29th, Toronto, Canada (2003).
   Google Scholar
• Hamner MB, Ulmer HG, Faldowski RA et al. A randomized controlled trial of risperidone for psychotic features in PTSD. Int. Clin. Psychopharmacol. 18, 1–8 (2003).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Deitsch SE, Brodrick PS et al. Quetiapine treatment in PTSD: an open trial of adjunctive therapy. J. Clin. Psychopharmacol. 23, 15–20 (2003).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J. Clin. Psychiatry 61(Suppl. 3), 4–9 (2000).
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Sanger TM, Beasly CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol. Psychiatry 43, 803–810 (1998).
   PubMed Web of Science ®Google Scholar
• Sattar SP, Ucci B, Grant K, Bhatia SC, Petty F. Quetiapine therapy for posttraumatic stress disorder. Ann. Pharmacother. 36, 1875–1878 (2002).
   PubMed Web of Science ®Google Scholar
• Sokolski KN, Denson TF, Lee RT, Reist C. Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil. Med. 168, 486–489 (2003).
   PubMedGoogle Scholar
• Petty F, Brannon S, Casada J et al. Olanzapine treatment for posttraumatic stress disorder: an open-label study. Int. Clin. Psychopharmacol. 16, 331–337 (2001).
   PubMed Web of Science ®Google Scholar
• Stone RC, Petty F. Olanzapine treatment for torture survivors with PTSD – a case series. Poster presented at the 17th Annual Meeting of the International Society for Traumatic Stress Studies, December 6–9, New Orleans, LA, USA (2001).
   Google Scholar
• Petty F, Gajewski V, Borman P, Worchel J, Suris A, Teten A. Olanzapine treatment for PTSD: the continuation phase. Syllabus and proceedings summary for the American Psychiatric Association Annual Meeting, May 5–10, New Orleans, LA, USA, 149–150 (2001).
   Google Scholar
• Bartzokis G, Freeman TW, Roca V. Risperidone treatment for combat-related PTSD. Presented at the American Psychiatric Association Annual Meeting, May 5–10, New Orleans, LA, USA (2001).
   Google Scholar
• Monnelly EP, Ciraulo DA, Knapp C et al. Low dose risperidone as adjunctive therapy for irritable aggression in PTSD. J. Clin. Psychopharmacol. 23, 193–196 (2003).
   PubMed Web of Science ®Google Scholar
• Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am. J. Psychiatry 159, 1777–1779 (2002).
   PubMed Web of Science ®Google Scholar
• Reich DB, Winternitz S, Hennen J et al. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J. Clin. Psychiatry 65, 1601–1606 (2004).
   PubMed Web of Science ®Google Scholar
• Butterfield MI, Becker ME, Connor KM et al. Olanzapine in the treatment of posttraumatic stress disorder: a pilot study. Int. Clin. Psychopharmacol. 16, 197–203 (1993).
   Google Scholar
• Dillard ML, Bendfeldt F, Jernigan P. Use of thioridazine in post-traumatic stress disorder. South Med. J. 86, 1276–1278 (2001).
   Google Scholar
• Leyba CM, Wampler TP. Risperidone in PTSD. Psychiatric Serv. 49, 245–246 (1998).
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Sagud M, Mihaljevic-Peles A. Olanzapine in the treatment-resistant, combat-related PTSD – a series of case reports. Acta Psychiatr. Scand. 107, 394–396 (2003).
   PubMed Web of Science ®Google Scholar
• Labbate LA, Douglas S. Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD). Can. J. Psychiatry 45, 667–668 (2000).
   PubMedGoogle Scholar
• States JH, Dennis ST. Chronic sleep disruption and the re-experiencing cluster of posttraumatic stress disorder symptoms are improved by olanzapine: brief review of the literature and case-based series. Prim. Care Companion J. Clin. Psychiatry 5, 74–79 (2003).
   PubMedGoogle Scholar
• Robert S, Hamner MB, Kose S et al. Open-label quetiapine in PTSD: analysis of sleep data. Poster presented at the 19th Annual Meeting of the International Society of Traumatic Stress Studies, October 29 – November 2, Chicago, IL, USA (2003).
   Google Scholar